Contact:

John G. Nesbett/David K. Waldman	The Quigley Corporation
Lippert Heilshorn & Associates	Carl Fonash
(212) 838-3777	Shareholder Relations
dwaldman@lhai.com	(267) 880-1111

The Quigley Corporation Intends to File for Permission to Study Its Patent Pending Potential Treatment for Psoriasis and Other Skin Disorders

DOYLESTOWN, PA, September 3, 2003 (BUSINESS WIRE) -- The Quigley Corporation (Nasdaq: QGLY), www.quigleyco.com, a leading developer and marketer of diversified health products, today announced that Quigley Pharma, its wholly owned product development subsidiary, has finished the analysis of a preliminary study on topical composition QR-337.

The test was designed to investigate the composition's potential for the improvement of the appearance of the skin. Skin conditions, such as dryness, redness, flaking, scaling and cracking were observed to improve after topical treatment with QR-337. The positive preliminary results exceeded those which could be considered cosmetic and therefore indicate that the use of this new composition should be studied as a potential treatment for skin disorders. Continued testing will therefore have to be conducted under an Investigation New Drug application (IND). The Quigley Corporation is now preparing an IND for submission to the Food and Drug Administration to obtain permission to study and develop the formula as a prescription drug.

The Quigley Corporation filed and has pending a United States utility patent application directed to methods for improving the cosmetic appearance and the treatment or prevention of a variety of skin disorders, including psoriasis, by topical application of a proprietary Quigley topical product, code named QR-337.

Quigley Pharma's Chief Operating Officer, Richard Rosenbloom, MD, Ph.D., formulated the all-natural QR-337 topical compound and will guide the ongoing development and testing. The mission of Quigley Pharma is the development of naturally derived prescription drugs, cosmeceuticals, and dietary supplements.

The Quigley Corporation makes no representation that the Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow QR-337 to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation
(Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented Zinc Gluconate Glycine (ZIGG(TM)) lozenges, gums and sugar free tablets. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to Introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. Additional information about The Quigley Corporation is available on its Web site at www.quigleyco.com.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.